Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: GLP-1 RA


Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases

March 30th 2022

This systematic review and meta-analysis of RCTs found that use of GLP-1 RAs was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss (JAMA Internal Medicine)

Categories: Medication, News, Pathology
Tags: gallbladder, GLP-1 RA

Categories: Medication, Pathology
Tags: gallbladder, GLP-1 RA

Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials

March 13th 2022

Results of our meta-analysis revealed that GLP-1 RA treatment decreases urinary albumin excretion and albumin to creatinine ratio but it did not cause significant changes in creatinine levels and glomerular filtration rate (British Journal of Clinical Pharmacology)

Categories: Medication, Nephropathy, News
Tags: creatinine, GFR, GLP-1 RA

Categories: Medication, Nephropathy
Tags: creatinine, GFR, GLP-1 RA

Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations

February 18th 2022

Here, we review evidence on GLP-1 RA use in people living with T2DM and CKD and summarize renal outcomes from clinical studies. We provide practical considerations for GLP-1 RA use to provide an added benefit to guide treatment in this high-risk patient population (Diabetes Therapy)

Categories: Medication, Nephropathy, News
Tags: CKD, GLP-1 RA, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: CKD, GLP-1 RA, Type 2 Diabetes

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

November 24th 2021

Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health (Journal of Clinical Endocrinology & Metabolism)

Categories: Medication, News
Tags: GIP, GLP-1 RA, lipid, tirzepatide, Type 2 Diabetes

Categories: Medication
Tags: GIP, GLP-1 RA, lipid, tirzepatide, Type 2 Diabetes

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

October 1st 2021

In ADJUNCT ONE and ADJUNCT TWO, the efficacy and glycaemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function as the only identified variable impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in T1D. These findings support a role for GLP-1 RAs as adjuncts to insulin in T1D, warranting further study (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP-1 RA, liraglutide, Type 1 Diabetes

Categories: Medication
Tags: GLP-1 RA, liraglutide, Type 1 Diabetes

Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

September 28th 2021

Use of SGLT2 inhibitors versus GLP-1 RAs was associated with consistent reductions in HHF risk among T2D patients with and without CVD, although the absolute benefit was greater in patients with CVD. There were no large differences in risk for MI or stroke among T2D patients with and without CVD (Annals of Internal Medicine)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 RA, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: GLP-1 RA, SGLT2 inhibitors

Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials

August 31st 2021

In ADJUNCT ONE and TWO, the efficacy and glycemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function the only identified parameter impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in T1D (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP-1 RA, liraglutide, Type 1 Diabetes

Categories: Medication
Tags: GLP-1 RA, liraglutide, Type 1 Diabetes

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

July 28th 2021

We conclude that a fair comparison between GLP-1 RA CVOTs would involve post-hoc analysis re-grouping the patients into different cardiovascular risk categories based upon their baseline clinical parameters, in order to even out the criteria used to classify patients (Diabetology & Metabolic Syndrome)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 RA

Categories: Cardiovascular, Medication
Tags: GLP-1 RA

GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials

June 15th 2021

Subgroup analyses suggested that treatment with GLP-1 RAs has a beneficial effect on cardiovascular outcomes irrespective of baseline use of metformin. However, given the exploratory nature of subgroup analyses, these findings should be treated as hypothesis-generating rather than conclusive evidence (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: GLP-1 RA, metformin

Categories: Medication
Tags: GLP-1 RA, metformin

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes

April 29th 2021

Early combination therapy with two and sometimes three of the DMDs (SGLT2i and GLP-1 RA) and metformin, and lower HbA1c targets (< 6.5%), may halt and even regress the pathological basis of diabetes and improve patient’s prognosis (Cardiovascular Diabetology)

Categories: Management, Medication, News
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

Categories: Management, Medication
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

October 25th 2020

Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines (Cardiovascular Diabetology)

Categories: News, Treatment
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

Categories: Treatment
Tags: GLP-1 RA, SGLT2 inhibitors, Type 2 Diabetes

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data

April 27th 2019

Across six countries, persistence was highest among DULA patients and generally lowest among exBID patients. ADD/AWD for all GLP-1 RAs was in line with the recommended label. Longer-term data would be useful to obtain a better understanding of GLP-1 RA treatment patterns over time (Diabetes Therapy)

Categories: News
Tags: GLP-1 RA, Type 2 Diabetes

Categories:
Tags: GLP-1 RA, Type 2 Diabetes

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes!

July 22nd 2017

GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm (Diabetes Care)

Categories: News, Treatment
Tags: GLP-1 RA, metformin, Type 2 Diabetes

Categories: Treatment
Tags: GLP-1 RA, metformin, Type 2 Diabetes

Occurrence of nausea, vomiting, and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

November 10th 2016

GLP-1 RAs are associated with “gastrointestinal” AEs that are related to dose and background medications (especially metformin), and may vary in a compound-specific manner. Long-acting agents are associated with less nausea and vomiting but more diarrhoea (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: adverse events, GLP-1 RA

Categories: Medication
Tags: adverse events, GLP-1 RA

A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients

October 7th 2016

Slightly better glycaemic control can be achieved by adding GLP-1 RAs to OGLM as compared to insulin treatment, with added benefits regarding body weight, hypoglycaemia, blood pressure and lipoproteins. These differences are in contrast to insulin being prescribed far more often than GLP-1 RAs (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP-1 RA, insulin, Type 2 Diabetes

Categories: Medication
Tags: GLP-1 RA, insulin, Type 2 Diabetes

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

October 9th 2015

Given their dosing scheme and overall efficacy and safety profile, once-weekly GLP-1 RAs are a convenient therapeutic option for use as add-on to metformin (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP-1 RA

Categories: Medication
Tags: GLP-1 RA

Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA): Long-Term Effect on Kidney Function in Patients with Type 2 Diabetes

April 12th 2015

Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-hour SBP were reduced (Journal of Diabetes and Its Complications)

Categories: Nephrology, News
Tags: GLP-1 RA

Categories: Nephrology
Tags: GLP-1 RA

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesAstraZenecaBoehringer IngelheimNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership